Recent discussions on X about BridgeBio Pharma (BBIO) have centered around the company's strong performance and analyst endorsements. Many users are highlighting the initiation of coverage by major financial institutions, with some noting buy ratings and price targets as high as $66 to $70. There’s a sense of anticipation around upcoming quarterly results, with speculation on whether the numbers will meet high expectations.
Additionally, conversations reflect curiosity about the competitive landscape, especially following the successful launch of BridgeBio’s heart medication, Attruby, which has reportedly exceeded sales projections. Some users express cautious optimism, debating the stock’s current enterprise value and potential moves by major stakeholders. The dialogue captures a dynamic mix of confidence and scrutiny as the company navigates its growth trajectory.
Note: This discussion summary was generated from an AI condensation of post data.
BridgeBio Pharma Insider Trading Activity
BridgeBio Pharma insiders have traded $BBIO stock on the open market 37 times in the past 6 months. Of those trades, 0 have been purchases and 37 have been sales.
Here’s a breakdown of recent trading of $BBIO stock by insiders over the last 6 months:
- GENETIC DISORDER L.P. KKR has made 0 purchases and 2 sales selling 12,000,000 shares for an estimated $402,960,000.
- GLOBAL INVESTORS LP VIKING has made 0 purchases and 2 sales selling 6,565,616 shares for an estimated $260,989,998.
- NEIL KUMAR (Chief Executive Officer) has made 0 purchases and 18 sales selling 1,037,699 shares for an estimated $37,556,804.
- FRANK MCCORMICK sold 100,000 shares for an estimated $4,422,800
- ANDREW LO sold 100,000 shares for an estimated $3,849,900
- BRIAN C STEPHENSON (CFO and Treasurer) has made 0 purchases and 4 sales selling 80,648 shares for an estimated $2,899,849.
- ANDREA ELLIS has made 0 purchases and 2 sales selling 40,000 shares for an estimated $1,371,500.
- HANNAH VALANTINE has made 0 purchases and 6 sales selling 21,874 shares for an estimated $798,506.
- MARICEL APULI (Chief Accounting Officer) sold 1,026 shares for an estimated $39,509
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
BridgeBio Pharma Hedge Fund Activity
We have seen 182 institutional investors add shares of BridgeBio Pharma stock to their portfolio, and 115 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- KOHLBERG KRAVIS ROBERTS & CO. L.P. removed 6,000,000 shares (-23.8%) from their portfolio in Q1 2025, for an estimated $207,420,000
- VIKING GLOBAL INVESTORS LP removed 3,065,616 shares (-12.2%) from their portfolio in Q1 2025, for an estimated $105,978,345
- JANUS HENDERSON GROUP PLC added 2,263,866 shares (+46.1%) to their portfolio in Q1 2025, for an estimated $78,261,847
- DEEP TRACK CAPITAL, LP added 1,980,838 shares (+241.8%) to their portfolio in Q1 2025, for an estimated $68,477,569
- CITADEL ADVISORS LLC added 1,675,672 shares (+133.5%) to their portfolio in Q1 2025, for an estimated $57,927,981
- FARALLON CAPITAL MANAGEMENT LLC added 1,536,000 shares (+36.6%) to their portfolio in Q1 2025, for an estimated $53,099,520
- DRIEHAUS CAPITAL MANAGEMENT LLC added 1,500,558 shares (+inf%) to their portfolio in Q1 2025, for an estimated $51,874,290
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BridgeBio Pharma Analyst Ratings
Wall Street analysts have issued reports on $BBIO in the last several months. We have seen 13 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Jefferies issued a "Buy" rating on 07/14/2025
- Citigroup issued a "Buy" rating on 07/11/2025
- Oppenheimer issued a "Outperform" rating on 07/09/2025
- Wells Fargo issued a "Overweight" rating on 06/30/2025
- B of A Securities issued a "Buy" rating on 06/25/2025
- Wolfe Research issued a "Outperform" rating on 06/17/2025
- HC Wainwright & Co. issued a "Buy" rating on 06/09/2025
To track analyst ratings and price targets for BridgeBio Pharma, check out Quiver Quantitative's $BBIO forecast page.
BridgeBio Pharma Price Targets
Multiple analysts have issued price targets for $BBIO recently. We have seen 14 analysts offer price targets for $BBIO in the last 6 months, with a median target of $63.0.
Here are some recent targets:
- Danielle Brill from Truist Securities set a target price of $66.0 on 07/21/2025
- Biren Amin from Piper Sandler set a target price of $68.0 on 07/14/2025
- Andrew Tsai from Jefferies set a target price of $70.0 on 07/14/2025
- David Lebowitz from Citigroup set a target price of $67.0 on 07/11/2025
- Leland Gershell from Oppenheimer set a target price of $60.0 on 07/09/2025
- Tiago Fauth from Wells Fargo set a target price of $76.0 on 06/30/2025
- Geoff Meacham from B of A Securities set a target price of $54.0 on 06/25/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
